OXB enters into licensing agreement with Viral Vector Manufacturing Facility (VVMF), providing access to its AAV and LV viral vector platforms

Core Insights - OXB has entered into a licensing and option agreement with VVMF, Australia's first commercial manufacturing facility for viral vectors, to enhance its global reach in cell and gene therapy [1][2][4] Group 1: Agreement Details - The agreement grants VVMF a worldwide, non-exclusive license to OXB's inAAVate™ platform and an option for the LentiVector™ platform, with OXB receiving a low single-digit million license fee and potential future payments [2][3] - This five-year license aims to accelerate VVMF's operational and commercial readiness, focusing on the growing demand in the APAC region [3][4] Group 2: Strategic Implications - The collaboration reinforces OXB's position as a trusted provider of viral vector development and manufacturing services, highlighting the scalability and reliability of its platforms [4][5] - VVMF aims to leverage OXB's expertise to establish a leadership position in the APAC region, enhancing its operational capabilities and aligning with industry standards [6][5] Group 3: Company Background - OXB is a pioneer in cell and gene therapy with 30 years of experience in viral vectors, collaborating with leading pharmaceutical and biotechnology companies [9][12] - The company offers a range of technologies for viral vector manufacturing, including advanced systems for lentiviral and AAV production [10][9]